Heart valve disease (HVD) affects millions of people worldwide, with the prevalence increasing as the population ages. The condition often necessitates surgical intervention to either repair or replace the malfunctioning valve. While mechanical and biological prosthetic valves have been the mainstays of treatment for decades, they come with significant limitations including the need for lifelong anticoagulation, limited durability, and inability to grow with pediatric patients. Recent advancements in biofabrication and three-dimensional (3D) printing technologies are opening new frontiers for creating functional, patient-specific living heart valves that could overcome these drawbacks and potentially transform the standard of care.

Current Limitations of Traditional Heart Valve Replacements

Mechanical heart valves are durable and long-lasting, but they require patients to take anticoagulants indefinitely to prevent clot formation, which carries a risk of bleeding complications. Biological valves—either from porcine or bovine tissue—do not require anticoagulation but have a limited lifespan of 10–20 years, often requiring reoperation. Furthermore, neither type can grow, adapt, or remodel in response to the patient’s changing physiology, making them particularly problematic for children with congenital valve disease.

Another critical issue is the lack of self-repair capacity. Prosthetic valves cannot regenerate damaged tissue or respond to cellular signals. These limitations underscore the urgent need for a new generation of heart valves that mimic the complex structure, mechanical properties, and biological functionality of native valves. Biofabrication using 3D printing offers a potential pathway to achieve this goal by combining patient-specific geometry with living cells and biomaterials.

The Promise of Biofabrication and 3D Printing

Biofabrication integrates principles from biology, engineering, and materials science to construct living tissues and organs. When applied to heart valves, the goal is to create a tissue-engineered construct that can be populated with the patient’s own cells, eliminating the risk of immune rejection. 3D printing, or additive manufacturing, enables the precise, layer-by-layer deposition of bioinks—mixtures of living cells and biocompatible materials—into complex three-dimensional shapes that mirror the native valve anatomy.

This personalized approach allows for tailoring of valve dimensions, leaflet thickness, and compliance to each patient’s unique anatomy, which is particularly valuable for pediatric populations where growth and remodeling are essential. Additionally, incorporating multiple cell types and biomaterials in discrete regions can recapitulate the native valve’s layered architecture, including the fibrosa, spongiosa, and ventricularis layers.

Materials for Heart Valve Biofabrication

The choice of biomaterials and cells is critical to the success of biofabricated heart valves. These materials must be biocompatible, provide adequate mechanical strength, support cell adhesion and proliferation, and ideally degrade at a rate that matches new extracellular matrix (ECM) deposition.

Hydrogels

Hydrogels are water-swollen networks that closely mimic the natural ECM environment. Commonly used hydrogels in cardiac valve biofabrication include gelatin methacryloyl (GelMA), alginate, hyaluronic acid, and fibrin. GelMA is particularly attractive because it contains cell-adhesive motifs and can be enzymatically degraded by matrix metalloproteinases. Researchers have successfully printed GelMA-based bioinks containing valvular interstitial cells (VICs) and endothelial cells, achieving high cell viability and ECM production. However, hydrogels alone often lack sufficient mechanical stiffness, so they are frequently combined with tougher materials to form composite scaffolds.

Biodegradable Polymers

Synthetic biodegradable polymers such as polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), and poly(lactic-co-glycolic acid) (PLGA) provide the structural backbone for biofabricated valves. These polymers have well-characterized degradation rates and can be fabricated into fibrous meshes or solid frameworks using melt-extrusion, electrospinning, or selective laser sintering. For example, PCL is often used as a rigid support ring to maintain the valve’s annular shape, while softer polymers or hydrogels form the leaflets. The combination of a stiff polymeric skeleton with a compliant hydrogel matrix helps achieve the asymmetric mechanical behavior needed for proper valve opening and closing.

Cell Sources

Two major cell types are required for a functional heart valve: valvular interstitial cells (VICs) that synthesize and remodel ECM, and valvular endothelial cells (VECs) that line the surface and prevent thrombosis. Because obtaining autologous VICs and VECs from a patient is invasive and yields limited numbers, researchers often use stem cells such as mesenchymal stem cells (MSCs) or induced pluripotent stem cells (iPSCs). iPSC-derived VICs and VECs have been shown to recapitulate key phenotypic markers and can be expanded to sufficient quantities. Using the patient’s own iPSCs can eliminate immune rejection and provide cells capable of long-term tissue maintenance.

3D Printing Techniques for Heart Valve Fabrication

Several additive manufacturing techniques have been adapted for heart valve biofabrication, each with distinct advantages and limitations. The choice of method depends on the desired resolution, material compatibility, cell viability, and intricacy of the valve geometry.

Extrusion-Based Printing

Extrusion-based 3D printing uses a pneumatic or mechanical piston to deposit bioink filaments layer by layer. This method is widely employed because it can handle high cell densities (up to 10⁷ cells/mL) and a broad range of viscosities. For heart valves, multiphoton extrusion can simultaneously print multiple materials—for instance, a rigid PCL ring combined with a soft GelMA leaflet—to create heterogeneous constructs. The main limitation is the modest resolution (~100–500 μm), which may not capture fine leaflet details. However, recent improvements in coaxial extrusion and microfluidic printheads have enhanced precision.

Stereolithography (SLA)

Stereolithography uses ultraviolet light to selectively crosslink a photosensitive prepolymer resin. SLA offers high resolution (<50 μm) and smooth surface finishes, ideal for replicating the intricate geometry of valve leaflets and commissures. Digital light processing (DLP) variants can print entire layers at once, drastically reducing fabrication time. Researchers have used SLA to fabricate hydrogel-based valves with excellent shape fidelity and cell viability exceeding 85%. The main challenge is that cells are often suspended in a non-crosslinked resin, which can be toxic if exposure to UV light or photoinitiators is prolonged. New bioink formulations with lower cytotoxicity are under development.

Selective Laser Sintering (SLS)

SLS uses a focused laser to fuse powdered polymer particles into solid structures. This method is ideal for creating durable, porous scaffolds from medical-grade polymers like PCL and polyether ether ketone (PEEK). SLS-printed scaffolds can serve as permanent or slowly degrading supports that provide mechanical integrity while the cellular components mature. Because SLS operates at high temperatures, cells cannot be incorporated during printing; instead, cells are seeded post-printing onto the scaffold surface. This two-step approach can still yield functional valves, but achieving uniform cell distribution within thick scaffolds remains a challenge.

Other Emerging Techniques

Inkjet printing deposits picoliter droplets of bioink onto a substrate, enabling precise placement of multiple cell types and materials in a single pass. However, the low viscosity requirements limit the use of many hydrogels. Electrohydrodynamic (EHD) printing can produce micro- and nanoscale fibers, mimicking the collagen architecture of native leaflets. Additionally, volumetric bioprinting uses light patterns to crosslink a cell-laden resin in a 3D volume within seconds, greatly reducing fabrication time and improving cell distribution. These advanced methods are still in early stages but hold promise for next-generation heart valve biofabrication.

Key Challenges in Biofabricating Functional Heart Valves

Despite remarkable progress, several hurdles remain before biofabricated heart valves can be translated to the clinic. Overcoming these challenges requires multidisciplinary collaboration among engineers, biologists, and clinicians.

Biocompatibility and Immunogenicity

Even autologous cells may trigger inflammatory responses if the biomaterial degradation products or crosslinking agents are not fully removed. Hydrogels often contain unreacted methacrylate groups or photoinitiators that can be cytotoxic. Additionally, the ECM produced by stem cells may not recapitulate the native valve’s complex proteoglycan and collagen composition, potentially leading to calcification. Stringent in vitro and in vivo testing is needed to ensure safety and long-term functionality.

Mechanical and Hemodynamic Performance

A biofabricated valve must withstand the cyclic hemodynamic loading of the cardiac cycle: systolic pressures up to 120 mmHg in the aortic position and diastolic pressures near 80 mmHg. It must open fully and close without regurgitation. Achieving the nonlinear, anisotropic mechanical properties of native valves is extremely challenging. Many constructs are too soft, leading to prolapse, or too stiff, causing stenosis. Iterative computational modeling and experimental validation are used to optimize material distribution and print design.

Cell Viability and Maturation

During printing, cells experience shear stress, pressure, and potential thermal damage, which can reduce viability below acceptable thresholds. After printing, the construct must be cultured in a bioreactor that mimics physiological flow and pressure to promote ECM deposition and tissue maturation. This process can take weeks to months, during which the construct must remain sterile and free from contamination. Endothelialization of the valve surface is also critical to prevent thrombosis; achieving a confluent endothelial monolayer remains difficult, especially on curved or porous surfaces.

Scalability and Regulatory Hurdles

Taking a biofabricated heart valve from the lab bench to a reproducible manufacturing process that complies with Good Manufacturing Practices (GMP) is a monumental task. Batch-to-batch variability in cell quality, bioink composition, and print parameters must be minimized. Regulatory agencies such as the FDA require robust evidence of safety, efficacy, and quality control. Because biofabricated valves are living products, they raise unique questions about storage, transport, and shelf life. Few clinical trials have been initiated to date, and no product has received regulatory approval.

Emerging Technologies and Future Directions

The field of heart valve biofabrication is evolving rapidly, with new approaches being explored to address current limitations and move toward clinical reality.

4D Printing

4D printing adds a fourth dimension—time—by using shape-memory materials or stimuli-responsive hydrogels that change shape or stiffness in response to environmental cues (e.g., temperature, pH, or enzymatic activity). For heart valves, this could enable constructs that self-deploy or adjust their mechanical properties after implantation to adapt to the patient’s changing hemodynamics. Researchers have already demonstrated 4D-printed valve rings that contract when exposed to body temperature, potentially improving annulus fixation.

In Situ Biofabrication

In situ biofabrication uses minimally invasive approaches to print or assemble tissue constructs directly at the defect site inside the body. For example, a robotic arm equipped with a bioink extruder could be guided through a catheter to deposit cell-laden hydrogels onto the native valve annulus. This technique could reduce the complexity of ex vivo culturing and allow the body’s own regenerative mechanisms to integrate the construct. Early studies in animal models have shown feasibility for cartilage and bone repair, and adaptation for heart valves is an active area of research.

Personalized Medicine and Computational Modeling

Combining patient imaging (e.g., cardiac MRI or CT) with computational fluid dynamics (CFD) allows for patient-specific design optimization. By simulating the stresses and strains on the valve under physiological conditions, researchers can design leaflets with the optimal thickness, curvature, and material distribution. This digital twin approach can also guide the selection of print parameters to minimize regurgitation and maximize durability. The integration of artificial intelligence and machine learning is expected to further accelerate the design optimization process.

Clinical Trials and Translation Pathways

A few early-stage clinical trials are testing tissue-engineered heart valves (TEHVs) made from decellularized scaffolds seeded with the patient’s cells or produced using 3D-printed molds for cryopreserved homografts. For example, the ESPOIR trial is evaluating a tissue-engineered pulmonary valve in children. However, fully 3D-bioprinted living valves have not yet entered human trials. The road to regulatory approval will likely require stepwise validation in large animal models, followed by first-in-human studies in compassionate-use cases before broader clinical adoption.

Conclusion

Biofabrication of heart valves using 3D printing technologies is a rapidly advancing field that holds the potential to address the limitations of current prosthetic valves. By combining patient-specific geometry, living cells, and biocompatible materials, researchers aim to create valves that can grow, remodel, and function indefinitely. While significant challenges remain—mechanical performance, cell maturation, scalability, and regulatory approval—continued innovation in materials science, printing techniques, and tissue engineering is steadily moving the field toward clinical translation. For patients with heart valve disease, particularly children and young adults, these living valve replacements may one day offer a one-time solution that avoids the drawbacks of traditional prosthetics. Collaboration across disciplines and sustained investment in research will be essential to turn this promise into reality.